Loncar China BioPharma ETF (CHNA)
|Ex-Dividend Date||Dec 29, 2021|
|Day's Range||20.11 - 20.85|
|Inception Date||Aug 14, 2018|
The Advisor attempts to invest all, or substantially all, of its assets in the component securities and depositary receipts that make up the index. The index seeks to track the performance of a modified equal-weighted portfolio of companies directly involved in the growth of China's pharmaceutical and biotech related industries.
Top 10 Holdings27.14% of assets
|Pharmaron Beijing Co Ltd Ordinary Shares - Class H||n/a||3.16%|
|WuXi Biologics (Cayman) Inc||2269.HK||3.11%|
|Hangzhou Tigermed Consulting Co Ltd Class H||n/a||3.00%|
|Wuxi AppTec Co Ltd||n/a||2.77%|
|Kintor Pharmaceutical Ltd Ordinary Shares||9939.HK||2.65%|
|Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H||n/a||2.60%|
|China Resources Pharmaceutical Group Ltd Registered Shs Unitary 144A/Reg S||3320.HK||2.60%|
|Akeso Inc Ordinary Shares||9926.HK||2.41%|
|Hansoh Pharmaceutical Group Co Ltd||3692.HK||2.33%|
|Dec 29, 2021||$3.0314286||Dec 31, 2021|
|Dec 30, 2020||$0.1546187||Jan 4, 2021|
|Dec 23, 2019||$0.04024942||Dec 26, 2019|
Check these China ETFs that beat the S&P 500 in the past week, which was U.S. equities?
Policy easing in the Chinese economy, cooling trade tensions with the United States and Beijing's efforts for more urbanization have boosted these sector ETFs in 2019.